|
See related Glivec cap information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Hong Kong: Zuellig/Macau: Four Star |
|
Contents |
Imatinib mesylate |
|
Indications |
Adult Newly diagnosed Ph+ chronic myeloid leukemia (CML) in chronic phase, blast crisis, accelerated phase or in chronic phase after failure of interferon-α therapy. Unresectable &/or metastatic malignant GI stromal tumors (GIST). Childn Ph+ chronic phase CML w/c recurred after stem cell transplant or resistant to interferon-α therapy.
Click to view Glivec detailed prescribing infomation |
|
Dosage |
Adult Chronic phase CML 400 once daily, may be increased to 600 mg Accelerated or blast crisis CML 600 mg once daily, may be increased to 800 mg (given as 400 mg bd). Unresectable &/or metastatic malignant GIST 400 or 600 mg/day. Childn Chronic phase CML 260-340 mg/m2 once daily.
Click to view Glivec detailed prescribing infomation |
|
Overdosage |
View Glivec overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken with food |
|
Contraindications |
[Click for Glivec detailed prescribing infomation] |
|
Special Precautions |
Hepatic or renal impairment. Fluid retention & edema, GI irritation, hemorrhage. Monitor wt, CBC & liver function regularly. Pregnancy & lactation (avoid).
Click to view Glivec detailed prescribing infomation |
|
Adverse Drug Reactions |
Nausea, vomiting, diarrhea, abdominal pain, edema, muscle cramps, musculoskeletal pain, myalgia, joint pain, rash, fatigue, headache, fluid retention, neutropenia, thrombocytopenia, hemorrhage.
View ADR Monitoring Form |
|
Drug Interactions |
CYP3A4 inhibitors/inducers, substrates of CYP3A4 or CYP2D6.
View more drug interactions with Glivec |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Storage |
View Glivec storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Glivec description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Glivec mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
